Journal
JOURNAL OF IMMUNOLOGY
Volume 188, Issue 10, Pages 5054-5062Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1102710
Keywords
-
Categories
Funding
- Program for Appropriate Technology in Health Malaria Vaccine Initiative
- GlaxoSmithKline Biologicals
- Royal Society [LJC/USA/2005/Hafalla]
- Wellcome Trust [079920, 063516]
- MRC [G0400225, G1000808, G1002624] Funding Source: UKRI
- Medical Research Council [G1000808, G1002624, G0400225] Funding Source: researchfish
Ask authors/readers for more resources
RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium fakiparum, is undergoing clinical trials. We report an analysis of cellular immune response to component Ags of RTS,S-hepatitis B surface Ag (HBs) and P falciparum circumsporozoite (CS) protein-among Tanzanian children in a phase IIb RTS,S/AS01(E) trial. RTS,S/AS01(E) vaccinees make stronger T cell IFN-gamma, CD69, and CD25 responses to HBs peptides than do controls, indicating that RTS,S boosts pre-existing HBs responses. T cell CD69 and CD25 responses to CS and CS-specific secreted IL-2 were augmented by RTS,S vaccination. Importantly, more than 50% of peptide-induced IFN-gamma(+) lymphocytes were NK cells, and the magnitude of the NK cell CD69 response to HBs peptides correlated with secreted IL-2 concentration. CD69 and CD25 expression and IL-2 secretion may represent sensitive markers of RTS,S-induced, CS-specific T cells. The potential for T cell-derived IL-2 to augment NK cell activation in RTS,S-vaccinated individuals, and the relevance of this for protection, needs to be explored further. The Journal of Immunology, 2012, 188: 5054-5062.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available